{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '151 Oyster Point Boulevard',
 'address2': 'Suite 400',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 8.6,
 'askSize': 1400,
 'averageDailyVolume10Day': 373900,
 'averageVolume': 669250,
 'averageVolume10days': 373900,
 'beta': 0.690588,
 'beta3Year': None,
 'bid': 7.71,
 'bidSize': 1200,
 'bookValue': 1.519,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 7.93,
 'dayLow': 7.57,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.433,
 'enterpriseToRevenue': 1.746,
 'enterpriseValue': 135450064,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '650 351 0353',
 'fiftyDayAverage': 8.309143,
 'fiftyTwoWeekHigh': 15.44,
 'fiftyTwoWeekLow': 3.595,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 37168405,
 'forwardEps': -2.56,
 'forwardPE': -3.0312502,
 'fromCurrency': None,
 'fullTimeEmployees': 158,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.02296,
 'heldPercentInstitutions': 0.84315,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/cytomx.com',
 'longBusinessSummary': 'CytomX Therapeutics, Inc. operates as an '
                        'oncology-focused biopharmaceutical company in the '
                        'United States. The company develops a novel class of '
                        'investigational antibody therapeutics based on its '
                        'Probody technology platform for the treatment of '
                        'cancer. Its product candidates in clinical stage '
                        'include CX-072, a Probody therapeutic targeting '
                        'programmed cell death ligand 1 immuno-oncology '
                        'target; CX-2009, a Probody drug conjugate (PDC) '
                        'against CD166 novel drug target; BMS-986249, a CTLA-4 '
                        'Probody therapeutic drug for the treatment of '
                        'metastatic melanoma; CX-2029, a PDC targeting CD71 '
                        'for solid tumors; and BMS-986288, an anti-CTLA-4 '
                        'Probody drug for solid tumors. The company has '
                        'strategic collaborations with AbbVie Ireland '
                        'Unlimited Company, Amgen, Inc., Bristol-Myers Squibb '
                        'Company, ImmunoGen, Inc., Pfizer Inc., and Astellas '
                        'Pharma Inc. to develop Probody therapeutics. CytomX '
                        'Therapeutics, Inc. was founded in 2008 and is '
                        'headquartered in South San Francisco, California.',
 'longName': 'CytomX Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 356364032,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_60504284',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -75909000,
 'nextFiscalYearEnd': 1640908800,
 'open': 7.7,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 10.23,
 'phone': '650 515 3185',
 'previousClose': 7.92,
 'priceHint': 2,
 'priceToBook': 5.108624,
 'priceToSalesTrailing12Months': 4.5924973,
 'profitMargins': -0.97824997,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 7.93,
 'regularMarketDayLow': 7.57,
 'regularMarketOpen': 7.7,
 'regularMarketPreviousClose': 7.92,
 'regularMarketPrice': 7.7,
 'regularMarketVolume': 540961,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45923200,
 'sharesPercentSharesOut': 0.0691,
 'sharesShort': 3171086,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 1196915,
 'shortName': 'CytomX Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0709,
 'shortRatio': 4.49,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'CTMX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.671,
 'twoHundredDayAverage': 8.168201,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'c5953a3e-48a3-3ef1-b8e7-58afa2ecd58e',
 'volume': 540961,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.cytomx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}